PharmaEssentia Corporation PharmaEssentia Corporation

PharmaEssentia Corporation

6446

Pozycja w akcjach #1440
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Cena akcji
$36.89
Kapitalizacja rynkowa
$15.25B
Zmiana (1 dzień)
-1.28%
Zmiana (1 rok)
144.12%
Kraj
TW
Handel PharmaEssentia Corporation (6446)

Kategoria

Healthcare
Wskaźnik P/S dla PharmaEssentia Corporation (6446)
Wskaźnik P/S na dzień October 2026 TTM: 23.96
Według najnowszych raportów finansowych i ceny akcji PharmaEssentia Corporation, obecny wskaźnik P/S (TTM) wynosi 23.96. Na koniec 2023 wynosił 22.06.
Historia wskaźnika P/S dla PharmaEssentia Corporation od 2010 do 2026
Wskaźnik P/S na koniec każdego roku
Rok Wskaźnik P/S Zmień
2026 (TTM) 23.96 16.52%
2024 20.56 -6.80%
2023 22.06 -53.07%
2022 47.01 -58.98%
2021 114.59 181.19%
2020 40.75 -46.81%
2019 76.61 -94.54%
2018 1.40K -81.75%
2017 7.68K 27.57%
2016 6.02K 95.48%
2015 3.08K 61.64%
2014 1.91K 276.50%
2013 506.34 -45.75%
2012 933.30 -41.98%
2011 1.61K 237.00%
2010 477.29 0.00%
Wskaźnik P/S dla podobnych firm lub konkurentów